期刊文献+

银杏内酯缓释片的制备工艺筛选及体外释放度评价 被引量:14

Preparation of Ginkgolide Sustained-Release Tablets
原文传递
导出
摘要 目的:研究银杏内酯缓释片的制备方法,并考察其体外释放特性。方法:以银杏内酯A(GA)和银杏内酯B(GB)释放度为考察指标,采用单因素试验法,考察了羟丙基甲基纤维素(HPMC)不同规格及用量,乳糖用量、低取代羟丙基纤维素(L-HPC)、羧甲基淀粉钠(CMS-Na)的用量对药物体外释放行为的影响,并采用正交设计实验对处方进行优化,确定最佳制备工艺条件。结果:以羟丙基甲基纤维素(HPMCK4M)为骨架材料,低取代羟丙基纤维素(L-HPC)为崩解剂,微晶纤维素和乳糖为填充剂,制备了每天给药1次的银杏内酯缓释片。该制剂2 h释放约30%,6 h释放约60%,12 h释放90%以上,满足缓释片释放要求。结论:本方法制备的银杏内酯缓释片外观及可压性良好,具有良好的释放性能。且工艺简单易行,生产成本低。 Objective:To study the method of preparing ginkgolides sustained-release tablets and investigate its vitro release characteristics. Method : the release of ginkgolides A (GA) and ginkgolides B (GB) was used as indicators to evaluate and optimize the formulation. The effets of hydroxypropyl methyl cellulose(HPMC) type and a- mount,the lactose amount,low-substituted hydroxypropyl cellulose(L-HPC) amount and carboxymethyl starch sodi- um(CMS-Na) amount on release behavior in vitro were observed in single-factor testing method. Then the formulation was optimized by orthogonal design test to determine the best preparation technological conditions. Result:The sustained-release tablets which were taken once a day, were prepared with HPMCK4M as matrix, low-substituted hydroxypropyl cellulose as disintegrant,microerystalline cellulose and lactose as fillers. The tablets released 30% in 2 h, 60% in 6 h, and exceeding 90% in 12 h, meeting the requirements for sustained-release. Conclusion: Ginkgolides sustained-release tablets prepared in this method has good behavior of release characteristics. The shape of tablets and compressibility were good. The preparative technology is also simple with low producing cost.
出处 《中国实验方剂学杂志》 CAS 北大核心 2011年第5期12-16,共5页 Chinese Journal of Experimental Traditional Medical Formulae
基金 国家重大新药创制创新中药中试放大研究技术平台项目(2009ZX09313-032)
关键词 银杏内酯 缓释片 释放度 ginkgolide sustained-release tablet reslease rate
  • 相关文献

参考文献5

二级参考文献52

  • 1王建华,陈慧云,杨永,吕正检,徐世荣.口服缓/控释药物制剂技术研究进展[J].中国药业,2005,14(8):14-15. 被引量:9
  • 2邹盛勤,陈武,李开泉.乌索酸标准品的质量标准研究[J].医药导报,2005,24(12):1152-1154. 被引量:1
  • 3张钧寿.缓/控释制剂的国外研究动向[J].中国新药杂志,1996,5(3):161-164. 被引量:21
  • 4陈仲良.银杏提取物的化学成分和制剂的质量[J].中国药学杂志,1996,31(6):326-331. 被引量:102
  • 5[3]Singh BN,Kim KH.Floating drug delivery systems:an approach to oral controlled drug deliveryvia gastric retention[J].J Controlled Release,2000,63:235-259.
  • 6[7]Bettke KK,Fischer W.Development of multiple unit drug delivery system for the gastrointestinal tract[J].J Control Rel,1991,15(2):105.
  • 7[8]Cheng K,Zhu JB,Song XX,et al.Studies on hydroxypropyl methylcellulose donut-shaped tablets[J].Drug Dev Ind Pharm,1999,25(9):1067.
  • 8[1]Maruyama M,Terahara A,Nakanishi K.The inkgolides I.Isolation and characterization of the various groups[J].Tetrahedron Lett,1967,(4):299.
  • 9[4]Braquet P.The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN52021[J].Pharmacol Res Communi,1986,18(8):717.
  • 10[5]Krieglstein J.Neuroprotective effective of Ginkgo Biloba constituents[J].Eur J Pharmacol Sci,1995,3(1):39.

共引文献30

同被引文献121

引证文献14

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部